Boltz · siet Boltz-1: November 2024; Boltz-2: Juni 2025; Boltz Lab / Boltz PBC: 8. Januar 2026 · 5× · tolest 15. Okt. 2026
92
Momentum
Boltz is a biomolecular AI product from Boltz PBC, a public benefit corporation offering models and infrastructure for drug and molecule design. The offering includes the Boltz Lab platform with small-molecule and protein design agents and a hosted Boltz API. The model line ranges from the open-source Boltz-1 (MIT license) through Boltz-2 to closed-source successors such as Boltz-2.1 and BoltzMol-1.
Momentum-Verloop
18.07.16.10.
Features
| Compliance/Certification | SOC 2 Type 1 verified |
| Deployment Model | Multi-tenant, single-tenant, or fully on-premise |
| Use Case Scope | Biomolecular structure prediction, binding affinity prediction, small-molecule hit discovery, protein design |
| Integrations | Biomni Lab (bring-your-own API key); Claude Code, Codex, Gemini CLI plugins; partners: Pfizer, Takeda, GSK, dsm-firmenich |
| License | Boltz-2 and Boltz-1: MIT license (open source); Boltz-2.1 is closed-source |
| Platform | Boltz Lab (web platform with agents) and Boltz API (hosted inference, Python/JS SDKs) |
| Price | Boltz Lab: 200 free predictions/month, then from $0.025 per prediction (pay-as-you-go); Enterprise: custom |
| Release Date | Boltz PBC and Boltz Lab launched: January 8, 2026; Boltz-2: June 2025 |